

AWARD NUMBER: W81XWH-18-1-0601

TITLE: Safety and Feasibility of Emergency Preservation and Resuscitation for Cardiac Arrest from Trauma (EPR-CAT)

PRINCIPAL INVESTIGATOR: Samuel A. Tisherman, MD

CONTRACTING ORGANIZATION: University of Maryland

REPORT DATE: Sept 2019

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE Sept 2019		2. REPORT TYPE Annual		3. DATES COVERED 30 Aug 2018 – 29 Aug 2019	
4. TITLE AND SUBTITLE Safety and Feasibility of Emergency Preservation and resuscitation for Cardiac Arrest from Trauma (EPR-CAT)				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-18-1-0601	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Samuel A. Tisherman, MD E-Mail: stisherman@som.umaryland.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Maryland 220 Arch St. RM 02148 Baltimore, MD 21201 - 1531				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT During this first year of the project, we have continued enrollment at the Shock Trauma Center of the University of Maryland Medical Center, which had already begun enrollment under our previous grant, W81XWH-07-1-0682. We have added 1 subject who underwent Emergency Preservation and Resuscitation (EPR) and 1 control subject. This brings our totals to 5 EPR and 5 control subjects. None of these subjects have survived. We continue to conduct routine EPR drills to keep team members up to speed on the protocol. We have begun the process of bringing Stroger Hospital of Cook County on as a second EPR site. The subcontract with them has been completed. They have been developing the community consultation/public disclosure plan in concert with their Institutional Review Board. We are starting preparations for conducting training exercises for them once they receive regulatory approvals.					
15. SUBJECT TERMS Trauma, hemorrhagic shock, cardiac arrest, cardiopulmonary resuscitation, hypothermia					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	15	19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	7
5. Changes/Problems	8
6. Products	10
7. Participants & Other Collaborating Organizations	12
8. Special Reporting Requirements	15
9. Appendices	15

1. **INTRODUCTION:** *Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.*

Cardiopulmonary resuscitation (CPR) can save victims of normovolemic cardiac arrest (CA), e.g., ventricular fibrillation. During exsanguination CA from trauma, however, CPR, even with an emergency department (ED) thoracotomy and open chest CPR, results in unacceptably low survival rates (<5%). *Emergency Preservation and Resuscitation (EPR)* was developed to rapidly preserve the whole body during ischemia, using hypothermia, drugs, and fluids, to “buy time” for transport and resuscitative surgery. Laboratory research has only demonstrated efficacy from hypothermia. The purpose of this study is to test the feasibility of rapidly inducing profound hypothermia (10°C) with an aortic flush in trauma victims that have suffered CA and failed standard resuscitative efforts to enable resuscitative surgery and delayed resuscitation with cardiopulmonary bypass. The primary outcome variable will be survival to hospital discharge with minimal neurologic dysfunction.

2. **KEYWORDS:** *Provide a brief list of keywords (limit to 20 words).*

Trauma, hemorrhagic shock, cardiac arrest, cardiopulmonary resuscitation, hypothermia

3. **ACCOMPLISHMENTS:** *The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction.*

What were the major goals of the project?

List the major goals of the project as stated in the approved SOW. If the application listed milestones/target dates for important activities or phases of the project, identify these dates and show actual completion dates or the percentage of completion.

Specific Aims

1. Rapidly identify appropriate candidates for EPR
2. Initiate EPR and achieve goal temperature within 25 minutes of subject identification
3. Compare the rate of hospital discharge without major neurologic disability in the EPR group with the concurrent control group
4. Compare the rates of 28-day survival, 1-year neurologic functional outcome, and the development of multiple organ dysfunction in the EPR group with the concurrent control group
5. Document direct complications of the EPR technique

Major Task 1: Regulatory approvals

1. Local IRB approval of community consultation and public disclosure plan
2. Conduct community consultation/public disclosure
3. Local IRB Approval
4. US Army HRPO Approval

Major Task 2: Training

1. IACUC Approval
2. ACURO Approval
3. Complete animal training
4. Complete cadaver training

Major Task 3: Enroll patients in first 2 cohorts

1. Develop specific logistics with involved disciplines
2. Assure that all necessary equipment is ready
3. Subject enrollment at Site 1
4. Subject enrollment at Site 2
5. Enroll 10 EPR subjects and 10 control subjects

Major Task 4: Revise protocol

1. Evaluate data from first cohorts of 10 EPR and 10 control subjects
2. Revise protocol based upon data from first cohorts
3. Obtain approvals for second set of cohorts from DSMB, FDA, IRBs, and US Army HRPO

Major Task 5: Enroll patients in second 2 cohorts

1. Enroll 10 EPR subjects and 10 control subjects
2. Evaluate data from second set of cohorts of 10 EPR and 10 control subjects

What was accomplished under these goals?

For this reporting period describe: 1) major activities; 2) specific objectives; 3) significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative); and/or 4) other achievements. Include a discussion of stated goals not met. Description shall include pertinent data and graphs in sufficient detail to explain any significant results achieved. A succinct description of the methodology used shall be provided. As the project progresses to completion, the emphasis in reporting in this section should shift from reporting activities to reporting accomplishments.

Major Task 1: Regulatory approvals

All approvals have been completed at the University of Maryland.

During this year, we received approval for adding the John H. Stroger Hospital of Cook County (Hektoen Institute for Medical Research) as a second site. The subcontract with them has been finalized. Dr. Bokhari is working on regulatory approvals for the Hektoen Institute for Medical Research.

1. Local IRB approval of community consultation and public disclosure plan:
Dr. Bokhari has worked with his IRB and the institution's media relations group to develop the community consultation and public disclosure plan.
2. Conduct community consultation/public disclosure: plan for beginning in the next quarter
3. Local IRB Approval: pending completion of community consultation/public disclosure
4. US Army HRPO Approval: pending local IRB approval

Major Task 2: Training

Training has been completed at the University of Maryland, which has IACUC and ACURO approval. Animal and cadaver training for the team at Stroger Hospital will be completed at the University of Maryland, rather than at Stroger Hospital, when the regulatory approvals in Major Task 1 are closer to completion.

1. IACUC Renewal: completed
2. ACURO Renewal: submitted
3. Complete animal training: pending for Stroger Hospital
4. Complete cadaver training: pending for Stroger Hospital

Major Task 3: Enroll patients in first 2 cohorts

Enrollment is ongoing at the University of Maryland.

1. Develop specific logistics with involved disciplines: Discussions have begun at Stroger Hospital
2. Assure that all necessary equipment is ready: Discussions have begun at Stroger Hospital
3. Subject enrollment at Site 1: One EPR subject and one control subject have been enrolled at the University of Maryland during this year.
4. Subject enrollment at Site 2: pending approvals and training
5. Enroll 10 EPR subjects and 10 control subjects: in progress. We currently have 5 EPR subjects and 5 control subjects.

Major Task 4: Revise protocol

Pending completion of enrollment of the first cohort of 10 EPR and 10 control subjects.

1. Evaluate data from first cohort of 10 EPR and 10 control subjects
2. Revise protocol based upon data from first cohorts
3. Obtain approvals for second set of cohorts from DSMB, FDA, IRBs, and US Army HRPO

Major Task 5: Enroll patients in second 2 cohorts

1. Enroll 10 EPR subjects and 10 control subjects
2. Evaluate data from second cohorts of 10 EPR and 10 control subjects

What opportunities for training and professional development has the project provided?

If the project was not intended to provide training and professional development opportunities or there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe opportunities for training and professional development provided to anyone who worked on the project or anyone who was involved in the activities supported by the project. "Training" activities are those in which individuals with advanced professional skills and experience assist others in attaining greater proficiency. Training activities may include, for example, courses or one-on-one work with a mentor. "Professional development" activities result in increased knowledge or skill in one's area of expertise and may include workshops, conferences, seminars, study groups, and individual study. Include participation in conferences, workshops, and seminars not listed under major activities.

Nothing to report for this period. Training of the Stroger Hospital team members will begin once their regulatory approvals are closer to completion.

How were the results disseminated to communities of interest?

If there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe how the results were disseminated to communities of interest. Include any outreach activities that were undertaken to reach members of communities who are not usually aware of

these project activities, for the purpose of enhancing public understanding and increasing interest in learning and careers in science, technology, and the humanities.

Nothing to report.

What do you plan to do during the next reporting period to accomplish the goals?

If this is the final report, state “Nothing to Report.”

Describe briefly what you plan to do during the next reporting period to accomplish the goals and objectives.

We will continue to recruit subjects at the University of Maryland.

We will continue to work with the Stroger Hospital team to complete the community consultation/public disclosure process and proceed with regulatory approvals. When this process is close to completion, we will arrange for cadaver and animal training at the University of Maryland. Training should occur as close to the time of planned enrollment as possible.

IACUC renewal has been completed. We anticipate approval of the renewal from ACURO in the next quarter.

- 4. IMPACT:** *Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:*

What was the impact on the development of the principal discipline(s) of the project?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how findings, results, techniques that were developed or extended, or other products from the project made an impact or are likely to make an impact on the base of knowledge, theory, and research in the principal disciplinary field(s) of the project. Summarize using language that an intelligent lay audience can understand (Scientific American style).

Nothing to report.

What was the impact on other disciplines?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how the findings, results, or techniques that were developed or improved, or other products from the project made an impact or are likely to make an impact on other disciplines.

Nothing to report.

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe ways in which the project made an impact, or is likely to make an impact, on commercial technology or public use, including:

- *transfer of results to entities in government or industry;*
- *instances where the research has led to the initiation of a start-up company; or*
- *adoption of new practices.*

Nothing to report.

What was the impact on society beyond science and technology?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how results from the project made an impact, or are likely to make an impact, beyond the bounds of science, engineering, and the academic world on areas such as:

- *improving public knowledge, attitudes, skills, and abilities;*
- *changing behavior, practices, decision making, policies (including regulatory policies), or social actions; or*
- *improving social, economic, civic, or environmental conditions.*

Nothing to report.

- 5. CHANGES/PROBLEMS:** *The PD/PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, “Nothing to Report,” if applicable:*

Nothing to report.

Actual or anticipated problems or delays and actions or plans to resolve them

Describe problems or delays encountered during the reporting period and actions or plans to resolve them.

The cause for low enrollment at the University of Maryland is unclear. We are continuing to review our trauma registry and screening procedures with the research staff to be sure we are not missing potential subjects.

There was a delay in getting approval from DoD to change our subcontract from UT Houston to the John H. Stroger Hospital of Cook County. We have now completed the subcontract. Bringing on this second site should help with overall study enrollment.

Changes that had a significant impact on expenditures

Describe changes during the reporting period that may have had a significant impact on expenditures, for example, delays in hiring staff or favorable developments that enable meeting objectives at less cost than anticipated.

Delay in approval of the subcontract with Stroger Hospital has shifted subcontract expenditures into years 2 and 3 of this project.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Describe significant deviations, unexpected outcomes, or changes in approved protocols for the use or care of human subjects, vertebrate animals, biohazards, and/or select agents during the reporting period. If required, were these changes approved by the applicable institution committee (or equivalent) and reported to the agency? Also specify the applicable Institutional Review Board/Institutional Animal Care and Use Committee approval dates.

Significant changes in use or care of human subjects

There have been no changes to the care of human subjects or vertebrate animals.

IRB approval date: 14-May-2019

IACUC approval date: 05-Sept-2019

Maryland State Anatomy Board approval date: 08-Jun-2015.

USAMRMC Office of Research Protections cadaver approval: 16-Jul-2015 under Proposal Log Number 07152001, Award Number W81XWH-07-1-0682.

Significant changes in use of biohazards and/or select agents

Nothing to report.

6. **PRODUCTS:** *List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state “Nothing to Report.”*

- **Publications, conference papers, and presentations**

Report only the major publication(s) resulting from the work under this award.

Journal publications. *List peer-reviewed articles or papers appearing in scientific, technical, or professional journals. Identify for each publication: Author(s); title; journal; volume; year; page numbers; status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

Nothing to report.

Books or other non-periodical, one-time publications. *Report any book, monograph, dissertation, abstract, or the like published as or in a separate publication, rather than a periodical or series. Include any significant publication in the proceedings of a one-time conference or in the report of a one-time study, commission, or the like. Identify for each one-time publication: author(s); title; editor; title of collection, if applicable; bibliographic information; year; type of publication (e.g., book, thesis or dissertation); status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

Nothing to report.

Other publications, conference papers and presentations. *Identify any other publications, conference papers and/or presentations not reported above. Specify the status of the publication as noted above. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (*) if presentation produced a manuscript.*

Presentations regarding the background and protocol. No data has been presented.

1. “Emergency Preservation and Resuscitation”, Cecil Gray Eponymous Lectureship, Tri-Service Anaesthetic Society, London, England, 2018.
2. “The journey to extended preservation resuscitation in humans”, Peter Baskett Lectureship, London Trauma Conference, London, England, 2018.
3. “Reducing metabolic needs in hemorrhagic shock”, Trauma Hemostasis Oxygenation Research Remote Damage Control Research Symposium, Bergen, Norway, 2019.
4. “Will suspended animation ever become reality?”, World Congress of Surgery, Krakow, Poland, 2019.
5. “Can Hypothermia Save Exsanguinating Trauma Patients?”, American College of Surgeons Clinical Congress, San Francisco, CA, 2019

List the URL for any Internet site(s) that disseminates the results of the research activities. A short description of each site should be provided. It is not necessary to include the publications already specified above in this section.

The following website was developed for disseminating information about the study as part of the public disclosure process. There is currently no information regarding results on this site.

<https://www.umms.org/ummc/health-services/shock-trauma/news/body-cooling-study>

- **Technologies or techniques**

Identify technologies or techniques that resulted from the research activities. Describe the technologies or techniques were shared.

Nothing to report.

- **Inventions, patent applications, and/or licenses**

Identify inventions, patent applications with date, and/or licenses that have resulted from the research. Submission of this information as part of an interim research performance progress report is not a substitute for any other invention reporting required under the terms and conditions of an award.

Nothing to report.

- **Other Products**

Identify any other reportable outcomes that were developed under this project. Reportable outcomes are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment and /or rehabilitation of a disease, injury or condition, or to improve the quality of life. Examples include:

- data or databases;

- *physical collections;*
- *audio or video products;*
- *software;*
- *models;*
- *educational aids or curricula;*
- *instruments or equipment;*
- *research material (e.g., Germplasm; cell lines, DNA probes, animal models);*
- *clinical interventions;*
- *new business creation; and*
- *other.*

Nothing to report.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate “no change”.

Example:

Name: Mary Smith
Project Role: Graduate Student
Researcher Identifier (e.g. ORCID ID): 1234567
Nearest person month worked: 5

Contribution to Project: Ms. Smith has performed work in the area of combined error-control and constrained coding.

Funding Support: The Ford Foundation (Complete only if the funding support is provided from other than this award.)

Name: Samuel A. Tisherman, MD
Project Role: Principal investigator
Researcher Identifier (e.g. ORCID ID): 0000-0003-3810-3729
Nearest person month worked: 2
Contribution to Project: Manages all aspects of the study, including training, readiness for enrollment, data management and analysis, submission of regulatory documents, and coordination with all sites. Dr. Tisherman is the sponsor of the Investigation Device Exemption.

Name: Thomas Scalea, MD
Project Role: Co-investigator
Researcher Identifier (e.g. ORCID ID):
Nearest person month worked: 1
Contribution to Project: Training of surgeons involved in the project. Revisions to the clinical protocol. Identification of clinical sites.

Name: Leslie Sult, RN
Project Role: Research coordinator
Researcher Identifier (e.g. ORCID ID):
Nearest person month worked: 4
Contribution to Project: Assists with training. Assures that equipment is available and that personnel are prepared for subject enrollment. Supervises data collection.

Name: Faran Bokhari, MD
Project Role: Site principal investigator at John H. Stroger Hospital of Cook County
Researcher Identifier (e.g. ORCID ID):
Nearest person month worked: 1
Contribution to Project: Manage all aspects of the study at Stroger Hospital, including team oversight, data management, and submission of regulatory documents.

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

If the active support has changed for the PD/PI(s) or senior/key personnel, then describe what the change has been. Changes may occur, for example, if a previously active grant has closed and/or if a previously pending grant is now active. Annotate this information so it is clear what has changed from the previous submission. Submission of other support information is not necessary for pending changes or for changes in the level of effort for active support reported previously. The awarding agency may require prior written approval if a change in active other support significantly impacts the effort on the project that is the subject of the project report.

Nothing to report.

What other organizations were involved as partners?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe partner organizations – academic institutions, other nonprofits, industrial or commercial firms, state or local governments, schools or school systems, or other organizations (foreign or domestic) – that were involved with the project. Partner organizations may have provided financial or in-kind support, supplied facilities or equipment, collaborated in the research, exchanged personnel, or otherwise contributed.

Provide the following information for each partnership:

Organization Name:

Location of Organization: (if foreign location list country)

Partner’s contribution to the project (identify one or more)

- *Financial support;*
- *In-kind support (e.g., partner makes software, computers, equipment, etc., available to project staff);*
- *Facilities (e.g., project staff use the partner’s facilities for project activities);*
- *Collaboration (e.g., partner’s staff work with project staff on the project);*
- *Personnel exchanges (e.g., project staff and/or partner’s staff use each other’s facilities, work at each other’s site); and*
- *Other.*

Organization Name: Stroger Hospital of Cook County

Location of Organization: Chicago, IL

Partner's contribution to the project: Collaboration as second site for conducting the study.

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS: *For collaborative awards, independent reports are required from BOTH the Initiating Principal Investigator (PI) and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to <https://ers.amedd.army.mil> for each unique award.*

QUAD CHARTS: *If applicable, the Quad Chart (available on <https://www.usamraa.army.mil>) should be updated and submitted with attachments.*

9. **APPENDICES:** *Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.*